Clinical trials: Early Alzheimers Disease
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Cognition Disorders, Alzheimer Disease
Treatment for Early Memory Loss
The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults.
- Trial name
- NCT00042172
- Testing
- Donepezil, Ginkgo Biloba Extract
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Alzheimer Disease, Alzheimer Disease, Early Onset
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood…
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss
- Trial name
- NCT04733989
- Testing
- Biomarker Data Collection
- Where
- 16 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- GAP Innovations, PBC
Dementia, Mild Cognitive Impairment (MCI)
Early-Stage Partner in Care Living Alone Plus
EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training…
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- EPICLA+ (NCT06962111)
- Testing
- Psychoeducational skills training intervention
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Arizona State University
Alzheimer Disease, Early Onset
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a…
- Trial name
- ROAD (NCT03625401)
- Testing
- AD-35 60mg group
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Alzheimer Disease
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This is a Phase II, multicenter, open-label, single arm, PD study in participants with early (prodromal to mild) AD to evaluate the effect of a once weekly (Q1W) dosing regimen of gantenerumab on deposited amyloid as measured by…
- Trial name
- NCT04592341
- Testing
- Gantenerumab
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 192 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Mild Cognitive Impairment
Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
The physio-pathology of Alzheimer's disease (AD) remains unknown and there is no cure. Thus, the search for objective markers of preclinical first signs of cognitive impairment, is currently a major public health issue.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia
- Trial name
- NCT01815112
- Testing
- Magnetic resonance imaging, Positron emission tomography
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Alzheimer's Disease, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
According to the World Health Organization, China will become the "oldest" country in the world by 2050, with 35 percent of the elderly population.
- Trial name
- NCT06868030
- Volunteers
- 120 people
- Sponsor
- First Hospital of China Medical University
Alzheimers Disease
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 2 (NCT07170150)
- Testing
- Trontinemab
- Where
- 147 sites in United States, Argentina and 14 more
- Volunteers
- 1,060 people
- Sponsor
- Hoffmann-La Roche
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial)…
- Trial name
- NCT04468659
- Testing
- Lecanemab
- Where
- 107 sites in United States, Australia and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eisai Inc.
Alzheimers Disease, Dementia
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation.
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT05552157)
- Testing
- Remternetug (SC)
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Alzheimer s Disease
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
- Trial name
- NCT07764146
- Testing
- VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Voyager Therapeutics
Alzheimer Disease
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03444870
- Testing
- Gantenerumab
- Where
- 172 sites in United States, Australia and 13 more
- Volunteers
- 1,053 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Mild Cognitive Impairment
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States.
- Trial name
- GERAS-US (NCT02951598)
- Testing
- Florbetapir F 18 PET Scan
- Where
- 77 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Early Alzheimer's Disease
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
- Trial name
- APOLLOE4-LTE (NCT06304883)
- Testing
- Experimental: ALZ-801
- Where
- 41 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Alzheon Inc.
Alzheimer Disease, Early Onset, MCI
The Interactive Physical and Cognitive Exercise System
This study is intended to clarify the benefits to brain health and thinking processes that result from different forms of exercise.
- Conditions
- Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment
- Trial name
- iPACES™ (NCT03069391)
- Testing
- physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Union College, New York
Alzheimer Disease, Mild Cognitive Impairment
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia.
- Trial name
- NCT06467539
- Testing
- DAOIB plus AO
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Dementia of Alzheimer Type, Alzheimer Disease
Prevalence of Alzheimer's Disease Pathology in the Community
The goal of this observational study is to (I) study the proportion of people with Alzheimer's disease pathology in a large Norwegian population-based cohort of people aged 70 years or older and to (II) study longitudinal changes…
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment, Pathology
- Trial name
- HUNT4AD (NCT06719453)
- Volunteers
- 9,663 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Early Onset Alzheimer Disease, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- LEADS (NCT03507257)
- Testing
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Indiana University